The Impact Factor 2018 of Molecular Therapy - Oncolytics is
5.710, which is just updated in 2019.
Compared with historical Impact Factor data, the Impact Factor 2018 of Molecular Therapy - Oncolytics grew by
The Impact Factor Quartile of Molecular Therapy - Oncolytics is
The Impact Factor (IF) or Journal Impact Factor (JIF) of an academic journal is a scientometric index that reflects the yearly average number of citations that recent articles published in a given journal received. It is frequently used as a proxy for the relative importance of a journal within its field; journals with higher impact factors are often deemed to be more important than those with lower ones. The Impact Factor measures the average number of citations received in a particular year (2018) by papers published in the journal during the two preceding years (2016-2017). Note that 2018 impact factors are reported in 2019; they cannot be calculated until all of the 2018 publications have been processed by the indexing agency.
Besides, 83% scientific research articles published by Molecular Therapy - Oncolytics have received at least 1 citation in 2018. In addition to the 2-year Impact Factor, the 3-year Impact Factor and 5-year Impact Factor can provide further insights into the impact of Molecular Therapy - Oncolytics.
Molecular Therapy - Oncolytics - Impact Factor Trend Prediction System
Impact Factor Trend Prediction System provides an open, transparent, and straightforward platform to help academic researchers Predict future journal impact and performance through the wisdom of crowds. Impact Factor Trend Prediction System displays the exact community-driven Data without secret algorithms, hidden factors, or systematic delay.
The ISSN of Molecular Therapy - Oncolytics is 23727705. An ISSN is an 8-digit code used to identify newspapers, journals, magazines and periodicals of all kinds and on all media–print and electronic.
Molecular Therapy - Oncolytics - Open Access Journal
Molecular Therapy - Oncolytics is an Open Access (OA) Journal. Open Access stands for unrestricted access and unrestricted reuse. With Open Access, researchers can read and build on the findings of others without restriction. Much scientific and medical research is paid for with public funds. Open Access allows taxpayers to see the results of their investment.
Molecular Therapy - Oncolytics - Publisher
Molecular Therapy - Oncolytics is published by Cell Press,
which is located in the United Kingdom.
The Publication History of Molecular Therapy - Oncolytics covers 2016-ongoing.
Molecular Therapy - Oncolytics - Categories
Molecular Therapy - Oncolytics is a peer-reviewed scientific journal.
The scope of Molecular Therapy - Oncolytics covers
Cancer Research (Q1), Molecular Medicine (Q1), Oncology (Q1), Pharmacology (medical) (Q1).